peter attia glp-1 320 – AMA 64: New insights on agonists (Ozempic, Wegovy, Mounjaro) - efficacy, benefits, risks, and considerations in the rapidly evolving weight-loss drug landscape - The Drive Dr. Peter Attia: Exercise, Nutrition,

Shmerling, MD Senior Faculty Editor, Harvard Health Publishing

has served on scientific advisory panels and/or speaker's bureaus and served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Fractyl, Gubra, Merck Sharp & Dohme, Novo Nordisk, Sanofi and Zealand Pharma

The products are high in protein, offer a good source of fiber and nutrients, and are portion-aligned to a weight loss medication users appetite

It also supports bone health (since bones stay stronger when you do weight-bearing activities)

De Baere I, Derua R, Janssens V, et al

You can also log in to your health insurance portal to access policy documents